Recombinant tissue-type plasminogen activator at 3 to 5 hours after ischemic acute stroke onset was not effective or safePDF
ACP J Club. 2000 July-Aug;133:18. doi:10.7326/ACPJC-2000-133-1-018
Related Content in this Issue
• Companion Abstract and Commentary: Intra-arterial recombinant prourokinase improved neurologic recovery in acute middle cerebral artery ischemic stroke
Clark WM, Wissman S, Albers GW, et al., for the ATLANTIS Study Investigators. Recombinant tissue-type plasminogen activator (alteplase) for ischemic stroke 3 to 5 hours after symptom onset. The ATLANTIS study: a randomized controlled trial. JAMA. 1999 Dec 1;282:2019-26. [PubMed ID: 10591384]
In patients who are treated between 3 and 5 hours after acute ischemic stroke onset, does recombinant tissue-type plasminogen activator (rt-PA) improve clinical outcome?
Randomized (allocation concealed*), blinded (patients, clinicians, and outcome assessors),* placebo-controlled trial with 90-day follow-up (Alteplase ThromboLysis for Acute Noninterventional Therapy in Ischemic Stroke [ATLANTIS]).
140 centers in North America.
613 patients who were 18 to 79 years of age (mean age 66 y, 59% men), had a clinical diagnosis of ischemic stroke with a measurable neurologic deficit, and received the study drug within 3 to 5 hours of symptom onset. Exclusion criteria included history or presence of other neurologic conditions, evidence of hemorrhage on computed tomography, history of stroke in previous 6 weeks, hypertension, recent trauma or hemorrhage, presumed septic embolism, conditions related to recent acute myocardial infarction, recent surgery or biopsy of a parenchymal organ, or other serious medical conditions. All patients were included in the analysis.
After stratification by clinical center, patients were allocated to rt-PA, 0.9 mg/kg of body weight (maximal dose 90 mg) (n = 307), or placebo (n = 306). rt-PA was given in a 1- to 2-minute intravenous bolus (10% of dose) and a 60-minute infusion (90% of dose).
Main outcome measures
Proportion of patients with excellent neurologic recovery (score ≤ 1 on the National Institutes of Health Stroke Scale). Serious adverse events were also assessed.
Analysis was by intention to treat. At 90 days, the groups did not differ for neurologic recovery (P > 0.2) or death (P = 0.08) (Table). rt-PA led to more asymptomatic (P = 0.001), symptomatic (P < 0.001), and fatal (P < 0.001) intracerebral hemorrhages than did placebo (Table).
Recombinant tissue-type plasminogen activator at 3 to 5 hours after acute ischemic stroke onset did not improve neurologic recovery and increased the risk for intra-cerebral hemorrhage.
Source of funding: Genentech Inc.
For correspondence: Dr. W.M. Clark, Oregon Stroke Center, UHS 44, Oregon Health Sciences University, 3181 S.W. Sam Jackson Park Road, Portland, OR 97201, USA. FAX 503-494-4690.
Table. Recombinant tissue-type plasminogen activator (rt-PA) vs placebo for acute ischemic stroke within 3 to 5 hours of onset†
|Outcomes||rt-PA||Placebo||RBI (95% CI)||NNT (CI)|
|Excellent neurologic recovery at 90 d||34.5%||34.0%||1.6% (-18 to 27)||Not significant|
|RRI (CI)||NNH (CI)|
|Asymptomatic ICH at 18 to 30 h||11%||4.2%||168% (47 to 394)||14 (9 to 34)|
|Symptomatic ICH at 18 to 30 h||6.8%||1.3%||423% (91 to 1346)||19 (12 to 39)|
|Fatal ICH at 18 to 30 h||2.6%||0.3%||697% (31 to 4798)||44 (21 to 208)|
|Death at 90 d||11%||6.9%||57% (-7 to 163)||Not significant|
†ICH = intracerebral hemorrhage. Other abbreviations defined in Glossary; RBI, RRI, NNT, NNH, and CI calculated from data in article.
Although the findings appear contradictory, results from the studies by Clark and Furlan and their colleagues contribute substantially to our understanding of thrombolytic therapy for acute ischemic stroke. On the basis of results from the U.S. National Institute of Neurologic Disorders and Stroke (NINDS) study in 1995 (1), the only treatment for acute ischemic stroke that is currently approved by the U.S. Food and Drug Administration is intravenous rt-PA when given within 3 hours of symptom onset. The ATLANTIS study of intravenous rt-PA treatment between 3 and 5 hours after stroke onset along with 2 previous European studies of intravenous rt-PA given within 6 hours of symptom onset (2, 3) have all failed to show substantial benefit in patients receiving rt-PA beyond 3 hours.
Results from 2 recent studies of intravenous rt-PA used outside the clinical trial setting showed that approximately 13% of patients treated with intravenous rt-PA were treated beyond the 3-hour window (4, 5). Whereas the rate of symptomatic intracerebral hemorrhage was 3.3% in 1 report (one half of the rate seen in the NINDS trial), this study was done primarily at centers with substantial experience in administering thrombolytic therapy (4). In a community-based study of 29 hospitals in the Cleveland area (5), the rate of symptomatic intracerebral hemorrhage was a sobering 15.7%. Although symptomatic intracerebral hemorrhage was not significantly associated with protocol deviations in either study, these observations, when viewed in light of the findings from ATLANTIS, underscore the need for adherence to established guidelines for intravenous rt-PA treatment.
The PROACT II study included only patients with angiographically documented occlusion of the middle cerebral artery; the prognosis for these patients is much poorer than for those with most other causes of stroke. As expected, spontaneous recovery to functional independence occurred in only 25% of patients in the control group. Therefore, the study was able to show a significant benefit with treatment, despite a 10% rate of symptomatic intracerebral hemorrhage.
Because the administration of an intra-arterial thrombolytic agent requires substantial technological resources, its applicability in the general community may be limited at present. Identifying eligible patients requires recognition of the clinical signs of a large hemispheric infarction and probably a noninvasive imaging test that suggests occlusion of the middle cerebral artery. Previous concerns about the practical aspects of evaluating and treating patients with acute stroke within 3 hours with intravenous rt-PA were never validated, and safe, effective use of rt-PA has been shown.
Fewer than 5% of all patients who have a stroke in the United States each year are treated with thrombolytic therapy. The leading barrier to treatment is patient arrival beyond the time limit for intervention, and the results from the ATLANTIS study clearly discourage treatment with intravenous rt-PA beyond 3 hours.
Expanding the time frame for intervention by using alternative means of delivery may increase the number of patients with acute stroke who can be safely treated with thrombolytic therapy. Whereas the ATLANTIS study has reaffirmed the time limitations of intravenous thrombolysis, the PROACT II study has redefined the window of opportunity for alternative methods of thrombolysis, at least in some patients.
Curtis G. Benesch, MD, MPH
Robert G. Holloway, MD, MPH
University of Rochester
Rochester, New York, USA
2. Hacke W, Kaste M, Fieschi C, et al. Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. The European Cooperative Acute Stroke Study (ECASS). JAMA. 1995;274:1017-25.
3. Hacke W, Kaste M, Fieschi C, et al. Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Second European-Australasian Acute Stroke Study Investigators. Lancet. 1998;352:1245-51.
4. Albers GW, Bates VE, Clark WM, et al. Intravenous tissue-type plasminogen activator for treatment of acute stroke: the Standard Treatment with Alteplase to Reverse Stroke (STARS) study. JAMA. 2000;283:1145-50.